X

Trial Profile

A Phase Ib/IIa Open-label, Repeated Dose, Metabolic Balance Study of FE 203799 in Patients With Short Bowel Syndrome and Intestinal Insufficiency

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 26 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apraglutide (Primary)
Indications Short bowel syndrome
Focus Adverse reactions
Sponsors GLyPharma Therapeutic; Therachon

Most Recent Events

13 Oct 2020 Results presented at the 28th United European Gastroenterology Week
05 Feb 2020 Status changed from recruiting to completed.
07 Jan 2020 According to a VectivBio media release, top-line results of this study is expected by the end of the first quarter of 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com